Topics

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

2019-07-18 10:31:21 | BioPortfolio

Summary

A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory AML or MDS

Description

This is an open-label, single arm, dose escalation study in patients with relapsed or refractory AML or MDS. Treatment will be administered on an outpatient basis and all patients will receive CYC065 over 4-hour infusion once every 2 weeks on Day 1 and Day 15 in combination with venetoclax. One treatment cycle is 4 weeks.

Study Design

Conditions

AML

Intervention

CYC065, Venetoclax

Location

MD Anderson Cancer Center
Houston
Texas
United States
77030

Status

Recruiting

Source

Cyclacel Pharmaceuticals, Inc.

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-07-18T10:31:21-0400

Clinical Trials [122 Associated Clinical Trials listed on BioPortfolio]

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

This is an open-label, single arm, dose escalation study in patients with advanced cancers.

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing ...

Venetoclax and Chemotherapy In ALL

This research study is studying a medication called Venetoclax and a chemotherapy regimen as a possible treatment for Acute Lymphoblastic Leukemia. The drugs involved in this study are: ...

Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

Venetoclax and ibrutinib have complementary activity in clearing the disease across anatomical compartments. By combining ibrutinib with venetoclax, cells can be mobilized from tissues int...

PubMed Articles [27 Associated PubMed Articles listed on BioPortfolio]

Ibrutinib and Venetoclax for First-Line Treatment of CLL.

Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL). Preclinical inv...

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

The BCL2 inhibitor venetoclax has shown activity in patients with chronic lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with CLL and coexisting conditions i...

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.

The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Both significantly...

Bevacizumab synergizes with the BCL 2 inhibitor venetoclax to effectively treat B-cell non-Hodgkin's lymphoma.

Our present study has shown that a potential role for VEGF-A-mediated autocrine signalling to promote survival and proliferation of SU-DHL-6 cells, but they could not undergo apoptosis but rather decr...

Noncoding RNA genes in cancer pathogenesis.

By using chronic lymphocytic leukemia as target for discovery in cancer pathogenesis we discovered that the great majority of CLLs (75-85%) carry a deletion of miR-15a and miR-16-1 at 13q14. We also...

Medical and Biotech [MESH] Definitions

None available.

More From BioPortfolio on "CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Searches Linking to this Trial